CNCT19

BIOLOGICAL2 trials

Sponsors

Shandong University, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Large B-cell LymphomaRelapsed or Refractory Hematological Malignancies

Early Phase 1

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

Shandong UniversityRelapsed or Refractory Hematological Malignancies

Start: 2019-07-31End: 2022-04-30Target: 20Updated: 2019-07-08

Phase 1

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

CompletedNCT04690192

Institute of Hematology & Blood Diseases Hospital, ChinaLarge B-cell Lymphoma

Start: 2021-01-01End: 2024-12-30Updated: 2025-05-13

Related Papers

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma

Journal for ImmunoTherapy of Cancer2024-04-0125 citations